You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,492,356


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,492,356
Title:Methods of inhibiting tumor growth using TTK antagonists
Abstract: The present invention relates to methods for treating TTK positive breast cancers or soft-tissue sarcomas in a mammalian subject by administering a therapeutically effective amount of a TTK antagonist. The invention also provides compositions comprising a TTK antagonist and a HER-2 antagonist, as well as methods of diagnosing a basal-like breast cancer and methods of determining the prognosis of a subject having a cancer by assessing expression of TTK in a tumor sample from a subject.
Inventor(s): Pan; Guohua (Oakville, CA)
Assignee: University Health Network (Toronto, CA)
Application Number:12/808,159
Patent Claims:1. A method for treating TTK positive non-luminal breast cancer in a mammalian subject, comprising administering to the subject a therapeutically effective amount of a TTK antagonist, wherein said cancer is HER-2 positive breast cancer.

2. The method of claim 1, wherein the TKK antagonist is selected from the group consisting of a small interfering ribonucleic acid (siRNA) or an antisense oligonucleotide.

3. The method of claim 1, wherein the TTK antagonist is selected from the group consisting of an antibody, an antigen-binding fragment of an antibody, or a peptide.

4. The method of claim 1, wherein the TTK antagonist is selected from the group consisting of a small molecule or a peptidomimetic.

5. The method of claim 1, further comprising administering one or more other therapeutic agents.

6. The method of claim 5, wherein a HER-2 antagonist is also administered.

7. The method of claim 6, wherein said HER-2 antagonist is trastuzumab.

8. The method of claim 6, wherein said HER-2 positive breast cancer is estrogen receptor (ER) negative.

9. The method of claim 1, wherein said tumor is a metastatic tumor.

10. The method of claim 1, wherein said HER-2 positive tumor is estrogen receptor (ER) negative.

11. A method of treating a TTK positive breast cancer in a mammalian subject, wherein said breast cancer is HER-2 positive and ER negative, comprising administering to the subject a therapeutically effective amount of a TTK antagonist.

12. The method of claim 11, wherein the TKK antagonist is selected from the group consisting of a siRNA or an antisense oligonucleotide.

13. The method of claim 11, wherein the TTK antagonist is selected from the group consisting of an antibody, an antigen-binding fragment of an antibody, or a peptide.

14. The method of claim 11, wherein the TTK antagonist is selected from the group consisting of a small molecule or a peptidomimetic.

15. The method of claim 11, further comprising administering a HER-2 antagonist.

16. The method of claim 15, wherein the HER-2 antagonist is trastuzumab.

Details for Patent 8,492,356

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2027-12-21
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2027-12-21
Genentech, Inc. HERCEPTIN HYLECTA trastuzumab and hyaluronidase-oysk Injection 761106 02/28/2019 ⤷  Try a Trial 2027-12-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.